Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

9.88
+0.55005.89%
Post-market: 10.110.2285+2.31%19:59 EDT
Volume:5.45M
Turnover:54.32M
Market Cap:614.13M
PE:-7.91
High:10.93
Open:10.61
Low:9.46
Close:9.33
52wk High:11.45
52wk Low:4.50
Shares:62.16M
Float Shares:55.78M
Volume Ratio:3.29
T/O Rate:9.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.40
PE(LYR):-6.25

Loading ...

Sagimet Biosciences’ China data strengthens denifanstat case, says Clear Street

TIPRANKS
·
5 hours ago

Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell

MT Newswires Live
·
Yesterday

Sagimet Biosciences prices 8.75M shares at $10.00 in underwritten offering

TIPRANKS
·
Yesterday

Sagimet Biosciences - Prices 8.8 Mln Series a Common Shares at $10 Per Share

THOMSON REUTERS
·
Yesterday

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series a Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Yesterday

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

GlobeNewswire
·
Yesterday

Sagimet Biosciences - Suspends and Terminates ATM Prospectus Supplement for Series a Common Stock Effective Sept 30

Reuters
·
Yesterday

Sagimet Biosciences - Suspends and Terminates Atm Prospectus Supplement for Series a Common Stock Effective Sept 30 - SEC Filing

THOMSON REUTERS
·
Yesterday

Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial

TIPRANKS
·
Yesterday

Sagimet Reports 52-Week Phase 3 Open-Label Extension Data Showing 56.7% IGA Success for Denifanstat in Moderate to Severe Acne

Reuters
·
Yesterday

Sagimet Biosciences - Denifanstat Well-Tolerated over 52 Weeks with no Serious Adverse Events

THOMSON REUTERS
·
Yesterday

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at Eadv 2026

THOMSON REUTERS
·
Yesterday

Sagimet Biosciences Schedules Virtual KOL Event on Denifanstat Acne Program

Reuters
·
Sep 28

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
Sep 28

Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts

TIPRANKS
·
Sep 26

Sagimet Biosciences Down over 15%, on Pace for Largest Percent Decrease Since April 2025

Dow Jones
·
Sep 25

Sagimet Biosciences Price Target Announced at $7.00/Share by Goldman Sachs

Dow Jones
·
Sep 24

H.C. Wainwright Remains a Buy on Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
Sep 22

Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8

MT Newswires Live
·
Sep 09

Sagimet Biosciences Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 09